What was tested and in whom
Roche conducted a late-stage study in patients whose non-small cell lung cancer had metastasized and was partially driven by the KRAS G12C mutation. Participants had already received other therapies, including chemotherapy, before getting the experimental drug.
What stood out in the data
Divarasib kept patients alive nearly six months longer than sotorasib and adagrasib in the head-to-head comparison. Safety lined up with earlier readouts for divarasib and its class, and fewer patients experienced serious side effects or stopped the trial because of them.
Why this head-to-head matters
Investigators say going straight at the incumbent drugs, rather than an easier comparator like chemotherapy, makes the case more compelling. "It will replace the existing established KRAS G12C inhibitors," said Jia Luo of Dana-Farber Cancer Institute, adding that Roche took a risk by testing directly against current options. "They actually took this risk and it's paid off," she said. Calling the results "practice-changing data," Roche deputy chief medical officer Stefan Frings said, "There is a strong incentive to get a highly active life-prolonging therapy with a good safety profile to patients."
When complex developments are in the spotlight, sign up for the free Market Briefs newsletter to get clear daily context in five minutes
What is next and why investors care
Roche is also testing divarasib earlier in the disease: combining it with Merck's Keytruda as a potential chemotherapy-free option for newly diagnosed patients, and using it after surgery to try to keep cancer from returning. If momentum holds, the company could be tracking toward the Bloomberg-polled forecast of a little more than 1 billion Swiss francs in 2032 sales, with the head-to-head win providing the commercial narrative your portfolio will watch.
Even with complex science and market noise, stay informed with our free Market Briefs that distill the essentials each morning
